Page 34 - 04_May-2025

The world’s
first trauma
response
autoinjector
by MACH32
34
“
 The end goal is
to allow anyone
to save a loved
one from bleeding
to death.” —Marc Curial
After several years of product devel-
opment, fundraising and collaborative
research, MACH32’s autoinjector —
invented on the premise of making a
highly regulated drug more accessible
— ran into regulatory roadblocks of its
own. Both Health Canada and U.S. Food
and Drug Administration have raised
concerns about the new delivery method
and higher concentrations of TXA. “This
is a drug that’s been in existence for 30
years, and we know it’s safe. It has an
excellent safety record,” says Curial with
exasperation. “We know it saves lives, so,
what’s the big deal?”
The company is currently running
preclinical pharmacology trials with
the U.S. Department of Defense’s trauma
research team and hopes to get approval
for human trials by 2027. The co-
founders aren’t just hoping to see it
become the go-to tool for trauma care
of all kinds; they hope it will one day be
as common to every first-aid kit as gauze
and tweezers. “There’s a saying in med-
icine that all bleeding stops eventually,”
says Curial. “It’s our goal that the
bleeding stops when the patient’s heart
is still beating.” ED .